Biotech fractional CFOs in 2026: Charles River CFO vs SeatonHill Partners vs YH CFO Consulting vs BioMed Financial vs Flow Partners

A biotech board sees twelve months of cash in the forecast, but nobody can explain whether that cash reaches the next useful scientific milestone. Clinical vendors invoice late, development dates move, and a promising partnership payment is still conditional. Hiring a fractional CFO should improve the decisions behind the runway number, including what happens if the next financing takes longer.

Charles River CFO, SeatonHill Partners, YH CFO Consulting, BioMed Financial and Flow Partners publish relevant life sciences services. Their offers range from an accounting-supported finance function to senior personal leadership and programme-focused financial modelling. This comparison uses official material reviewed October 21, 2026. Fit judgments are editorial assessments, not provider rankings, independently tested outcomes or funding recommendations.

The quick comparison

Define the scientific decision the CFO must support

A useful brief starts with the next portfolio decision: keep funding every programme, accelerate one, renegotiate a commitment, or preserve cash until another readout. The executive needs inputs from clinical, scientific and operating leaders. Finance should expose assumptions and options; it should not silently replace those leaders' judgment about development progress.

Separate the monthly accounting work from the forecast and from authority to make commitments. Chiefory's CFO versus controller comparison helps define those boundaries. Ask each candidate to explain how unbilled work, vendor commitments and changed trial dates enter the management view. A tidy cash balance is insufficient when the outstanding obligations are uncertain.

Charles River CFO

Charles River CFO's life sciences practice combines fractional and interim CFO leadership with outsourced accounting. Its sector page covers long R&D cycles, scenario planning, clinical accruals, financial controls, audit preparation and public-company reporting. That breadth is a useful strength when a lean company lacks both senior direction and enough finance capacity to maintain dependable records.

Fit: consider it when leadership wants the reporting foundation and the board conversation to share an accountable owner. Ask how the proposed CFO and accounting team would reconcile a development plan with vendor statements and the monthly close. Request a description of the recurring handoff with the clinical operations lead, including who challenges missing or outdated estimates.

Limitation to resolve: a broad practice offering does not establish that every service or specialist is included. Name the executive, the supporting staff and their allocation in the proposal. A company preparing for public reporting has a different workload from a small private research business. Confirm escalation cover and reporting responsibilities so the engagement is sized to the actual stage rather than the firm's full service catalogue.

SeatonHill Partners

SeatonHill Partners' biotech and life sciences service explicitly offers fractional and interim CFO talent. Its published scope includes capital management, licensing and joint ventures, financial reporting, sale or IPO preparation, and commercialization. It also discusses the financial systems and distribution arrangements that become relevant as a company moves toward product sales.

Strength and fit: this is a relevant shortlist candidate when the financial question extends beyond funding another research period. A partnering negotiation or commercial launch needs someone who can connect the proposed deal with cash timing, operating capacity and reporting. Ask which named partner would lead those discussions and what comparable responsibilities that person personally held.

Limitation to resolve: a network of partners is not one interchangeable skill set. Require experience appropriate to the company's modality, development stage and proposed transaction. Distinguish financial analysis from the work retained by scientific, regulatory and legal specialists. Also establish who maintains forecasts between major deal discussions; transaction expertise has less practical value if the weekly spending decisions still rely on an unrefreshed operating model.

YH CFO Consulting

YH CFO Consulting presents a personally led life sciences finance offer spanning board materials, capital strategy, cash forecasting, reporting and FP&A. Its founder describes taking direct ownership of forecasts and finance work when internal teams are lean. The published services distinguish pre-revenue, commercial and scaling needs.

Strength and fit: direct senior involvement can suit a CEO who needs one person able to prepare the numbers, explain them and challenge the decisions they imply. Ask the proposed executive to work through a hypothetical delayed financing alongside an unchanged vendor commitment. The buying question is whether the discussion produces clear choices, assumptions and decision dates.

Limitation to resolve: a personally led model makes availability and continuity important. Agree the normal working allocation, board-meeting coverage and response arrangements during overlapping deadlines. Confirm which close, treasury and procurement tasks the provider will execute versus coordinate through existing staff. Its website separates prior executive achievements from its consulting services; buyers should request relevant references rather than treating earlier employer outcomes or illustrative charts as expected results of a new engagement.

BioMed Financial

BioMed Financial focuses on early and clinical-stage life sciences companies, including biotech, devices and diagnostics. Its service categories cover fractional CFO leadership, strategic financial advisory, partnering and exits, and back-office support. Its stated approach links financial planning with development milestones and investor or partner readiness.

Fit: consider it when the company needs its development roadmap translated into a finance narrative and an operating plan. Ask how the proposed engagement would handle a change in manufacturing timing or a revised study budget. A useful answer should connect the immediate cash effect with the milestone and the next leadership decision, while preserving the assumptions supplied by technical specialists.

Limitation to resolve: the presence of several service lines does not mean all are bundled. Specify whether bookkeeping, payables, payroll, partner negotiations and board preparation belong in the same agreement. Confirm the proposed executive's experience with the particular product and geography. Where back-office support is included, require clear ownership of reconciliations and vendor information so strategic advice rests on records the leadership team can inspect.

Flow Partners

Flow Partners' biotech offering emphasizes financial modelling, FP&A and fractional CFO advisory. Its sector material discusses programme-level R&D costs, milestone-linked runway, clinical and manufacturing commitments, and licensing-related cash flows. This makes its modelling orientation a useful distinction within the comparison.

Strength and fit: shortlist it when the board needs a more explicit connection between individual programmes and the amount of capital required to reach a decision point. Ask for the proposed model's input owners, refresh schedule and method for showing uncertain dates. The company should be able to explain what changes when one programme slips without hiding the effect inside a single aggregate burn assumption.

Limitation to resolve: advisory and modelling capacity should not be mistaken for an entire accounting department or unlimited executive availability. Confirm who owns the close, vendor reconciliation, board presentation and financing conversations. Request biotech-specific examples relevant to the mandate; the page also displays experience from other sectors. Evaluate the people and work proposed rather than treating a wide client list as evidence of identical depth across every life sciences discipline.

Selection criteria: buy a decision process that stays current

Give the shortlisted providers the same anonymized planning scenario. Include available cash, known vendor commitments, one delayed development activity and a financing assumption with a range of dates. Ask each to describe the first decisions they would support and the missing information they would request. This is a proposed evaluation exercise, not testing performed for this article.

Compare responsibility at three levels: maintaining reliable records, updating the operating forecast and leading the management decision. Then compare the staffing behind each level. A lower quoted retainer may exclude the execution work that another proposal includes; a broader package may add capacity the company already has. Ask for assumptions and exclusions before comparing cost.

Finally, agree how the engagement changes as the company progresses. Board cadence, vendor complexity and financing activity can alter the workload. Define triggers for extra capacity, an interim full-time phase or a permanent hire. Use the fractional CFO directory for broader discovery and find an executive with a brief that names the development stage, finance gaps and decisions ahead.

Which provider fits the current constraint?

Charles River CFO merits consideration when leadership and accounting infrastructure need to move together. SeatonHill Partners is relevant to partnering, transactions and commercialization. YH CFO Consulting offers a directly involved senior model, while BioMed Financial connects early-stage life sciences strategy with optional operational support. Flow Partners deserves attention when programme modelling is the immediate gap. Choose the executive and delivery arrangement that can keep the company's next milestone decision grounded in current evidence.